At a glance
ClinicalIndex Comparison RecordPhase 4Completed
Drug / intervention
ENALAPRIL VALSARTAN METHYLPREDNISONEdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IV Open Label Uncontrolled Trial of the Dual Blockade of the Renin Angiotensin System With Enalapril Plus Valsartan Combined With Oral Methylprednisolone for the Treatment of Proteinuria in IGA Nephropathy
In Brief
A Phase 4 clinical trial evaluating ENALAPRIL VALSARTAN METHYLPREDNISONE for IGA Nephropathy. Completed, across 1 site.
Detailed Summary
TO ASSESS THE EFFICACY OF THE RENIN ANGIOTENSIN SYSTEM PLUS STEROIDS TO DECREASE THE AMOUNT OF PROTEINURIA IN IGA NEPHROPATHY
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIGA Nephropathy
CountriesArgentina
Collaborators--
Timeline
Phase 4CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 1996
Study CompletionDec 2005
First PostedAug 2006
TodayJul 2026
First PostedAug 23, 2006
Enrollment StartJan 1, 1996
Study CompletionDec 1, 2005
TodayJul 2, 2026
Posted 19.9 years ago
Interventions
ENALAPRIL VALSARTAN METHYLPREDNISONEdrug